WHIM Syndrome Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies – X4 Pharmaceuticals, NIAID, GSK plc, Bristol Myers Squibb

Posted on
by

WHIM Syndrome Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies - X4 Pharmaceuticals, NIAID, GSK plc, Bristol Myers Squibb
DelveInsight’s “WHIM Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the WHIM Syndrome.

DelveInsight’s “WHIM Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the WHIM Syndrome, historical and forecasted epidemiology as well as the WHIM Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the WHIM Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; WHIM Syndrome Market Forecast

 

Some of the key facts of the WHIM Syndrome Market Report: 

  • The WHIM Syndrome market size was valued approximately USD 8 Million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In 2021, the total prevalent cases of WHIM Syndrome were the highest in the US, with around 70 cases, and lowest in Spain with around 10 cases
  • There were approximately 30 males and 40 females affected by WHIM Syndrome in the United States in 2021, and it is estimated that the prevalence will increase and reach up to 50 males and 75 females by 2032
  • Among EU5 countries, Germany had the highest number of prevalent cases of WHIM Syndrome (Around 20 cases) in 2021
  • Key WHIM Syndrome Companies: X4 Pharmaceuticals, National Institute of Allergy and Infectious Diseases, GSK plc, Bristol Myers Squibb Company, F-Hoffmann La Roche Ltd., Pfizer Inc., Johnson and Johnson Services, Inc., Horizon Therapeutics plc, Amgen, and Leadiant Biosciences, and others
  • Key WHIM Syndrome Therapies: Mavorixafor, Plerixafor, X4P-001, and others
  • The WHIM Syndrome epidemiology based on gender analyzed that males and females contributed approximately 30 and 45 WHIM Syndrome cases in 2021 in EU-5
  • The WHIM Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage WHIM Syndrome pipeline products will significantly revolutionize the WHIM Syndrome market dynamics.

 

WHIM Syndrome Overview

WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome is an ultra-rare and difficult-to-diagnose primary immunodeficiency disease. In almost all patients of WHIM syndrome, the disease is caused by “gain-of-function” mutations in the single gene that encodes for the CXCR4 receptor.

 

Get a Free sample for the WHIM Syndrome Market Report – 

https://www.delveinsight.com/sample-request/whim-syndrome-market

 

WHIM Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

WHIM Syndrome Epidemiology Segmentation:

The WHIM Syndrome market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of WHIM Syndrome
  • Prevalent Cases of WHIM Syndrome by severity
  • Gender-specific Prevalence of WHIM Syndrome
  • Diagnosed Cases of Episodic and Chronic WHIM Syndrome

 

Download the report to understand which factors are driving WHIM Syndrome epidemiology trends @ WHIM Syndrome Epidemiology Forecast

 

WHIM Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the WHIM Syndrome market or expected to get launched during the study period. The analysis covers WHIM Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the WHIM Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

WHIM Syndrome Therapies and Key Companies

  • Mavorixafor: X4 Pharmaceuticals
  • Plerixafor: NIAID

 

Discover more about therapies set to grab major WHIM Syndrome market share @ WHIM Syndrome Treatment Market

 

WHIM Syndrome Market Strengths

  • Emerging drugs like mavorixafor in late-stage clinical development with strong clinical data for treating neutropenia, lymphopenia, sustained improvements in infections and warts in WHIM syndrome patients
  • Support from regulatory authorities by granting ODD status, Breakthrough Designations, and rare pediatric disease designations to encourage clinical drug development for the treatment of ultra-rare diseases

 

WHIM Syndrome Market Opportunities

  • There are no disease-specific approved therapies for the treatment of WHIM syndrome
  • The first product approved for the treatment of WHIM is likely to get a first-mover advantage across the 7MM

 

Scope of the WHIM Syndrome Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key WHIM Syndrome Companies: X4 Pharmaceuticals, National Institute of Allergy and Infectious Diseases, GSK plc, Bristol Myers Squibb Company, F-Hoffmann La Roche Ltd., Pfizer Inc., Johnson and Johnson Services, Inc., Horizon Therapeutics plc, Amgen, and Leadiant Biosciences, and others
  • Key WHIM Syndrome Therapies: Mavorixafor, Plerixafor, X4P-001, and others
  • WHIM Syndrome Therapeutic Assessment: WHIM Syndrome current marketed and WHIM Syndrome emerging therapies
  • WHIM Syndrome Market Dynamics: WHIM Syndrome market drivers and WHIM Syndrome market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • WHIM Syndrome Unmet Needs, KOL’s views, Analyst’s views, WHIM Syndrome Market Access and Reimbursement 

 

To know more about WHIM Syndrome companies working in the treatment market, visit @ WHIM Syndrome Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. WHIM Syndrome Market Report Introduction

2. Executive Summary for WHIM Syndrome

3. SWOT analysis of WHIM Syndrome

4. WHIM Syndrome Patient Share (%) Overview at a Glance

5. WHIM Syndrome Market Overview at a Glance

6. WHIM Syndrome Disease Background and Overview

7. WHIM Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of WHIM Syndrome 

9. WHIM Syndrome Current Treatment and Medical Practices

10. WHIM Syndrome Unmet Needs

11. WHIM Syndrome Emerging Therapies

12. WHIM Syndrome Market Outlook

13. Country-Wise WHIM Syndrome Market Analysis (2019–2032)

14. WHIM Syndrome Market Access and Reimbursement of Therapies

15. WHIM Syndrome Market Drivers

16. WHIM Syndrome Market Barriers

17.  WHIM Syndrome Appendix

18. WHIM Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services